AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24767638
Drug: CEI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEI with 1 mg/mL ropivacaine (Group C)
Trial: 24767638
Drug: CEI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEI with 0.8 mg/mL bupivacaine (Group D)
Trial: 22364262
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg/day) with ursodeoxycholic acid (UDCA) (600 mg/day)
Trial: 20698351
Drug: Topical difluoromethylornithine
RxNorm normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical difluoromethylornithine (DFMO)
Trial: 20698351
Drug: Topical Triamcinolone
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Triamcinolone
Trial: 20698351
Drug: Topical difluoromethylornithine
RxNorm normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical difluoromethylornithine (DFMO) + Triamcinolone
Trial: 17442512
Drug: Kangxin capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangxin capsule
Trial: 11829697
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n = 1380)
Trial: 11829697
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (hormone therapy and placebo)
Trial: 10510146
Drug: L‐NMMA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (4 mg kg‐1 bolus, with 4 mg kg‐1 infusion)
Trial: 8731849
Drug: 200mg vitamin
RxNorm normalized name: vitamin B6 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg vitamin C twice a day for 3 months
Trial: 15560690
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 3 months
Trial: 11505744
Drug: Amlodipine (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5-10 mg once daily)
Trial: 6111965
Drug: Carbonated beverage
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbonated beverage with syrup of ipecac
Trial: 28364426
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) alone
Trial: 28364426
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) combined with zolpidem as needed
Trial: 25594222
Drug: 3-hour oral
RxNorm normalized name: nitroglycerin 0.3 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hour oral glucose tolerance test (OGTT) values (fasting, 1-hour, 2-hour, and 3-hour)
Trial: 25594222
Drug: Fasting glucose
RxNorm normalized name: FAST TAKE (GLUCOSE) METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose between 85 and 94 mg/dL
Trial: 25594222
Drug: Fasting OGTT
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting OGTT < 95 mg/dL
Trial: 21872979
Drug: β‐Blocker therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐Blocker therapy in patients without IHD
Trial: 18068613
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no additional drug)
Trial: 29437243
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment
Trial: 9649984
Drug: Epidural midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural midazolam 0.05 mg kg‐1 in 5 mL saline (Group B)
Trial: 9649984
Drug: Epidural midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural midazolam 0.05 mg kg‐1 in 10 mL saline (Group C)
Trial: 9649984
Drug: Epidural midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural midazolam 0.05 mg kg‐1 in 15 mL saline (Group D)
Trial: 9649984
Drug: Epidural midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural midazolam 0.05 mg kg‐1 in 3 mL saline (Group A)
Trial: 25591873
Drug: Diazoxide (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (7 mg/kg)
Trial: 20729034
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution inflated cuffs
Trial: 15671432
Drug: Calfactant (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calfactant (2 doses of 80 mL/m2)
Trial: 29682995
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of isosorbide dinitrate spray and chitosan gel
Trial: 18319224
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate spray
Trial: 29145771
Drug: Chitosan gel
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan gel
Trial: 23110494
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg) biannually
Trial: 21050332
Drug: Structured reminiscence
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured reminiscence protocol offered twice weekly for 6 weeks
Trial: 17379055
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of tacrolimus (1 mg capsules, twice daily for a total daily dose of 4 mg)
Trial: 15682350
Drug: TPV 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPV 250 mg to 1250 mg twice daily for 11 days followed by RTV 100 mg for 21 days
Trial: 15682350
Drug: TPV 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPV 500 mg and 750 mg with RTV 100 mg or 200 mg
Trial: 10623704
Drug: 5‐day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐day course of chronomodulated 5‐FU (700 mg/m(2)/d) and LV (300 mg/m(2)/d) with l‐OHP (125 mg/m(2), as a 6‐hour infusion)
Trial: 10623704
Drug: 5‐day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐day course of chronomodulated 5‐FU (700 mg/m(2)/d) and LV (300 mg/m(2)/d) without l‐OHP
Trial: 1337070
Drug: Azithromycin, 250
RxNorm normalized name: Azithromycin, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 250 mg bd for 2 days followed by 250 mg od for 8 days
Trial: 1337070
Drug: Doxycycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg bd for 14 days
Trial: 29061617
Drug: HEART score
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEART score calculation by physicians in daily practice
Trial: 19553404
Drug: Doripenem 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem 1000 mg infused over 4 hours
Trial: 18225515
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using Photosens (aluminum phthalocyanine) intravenously injected at a dose of 0.05 mg/kg, with laser irradiation at 675 nm and exposure light dose of 120 J/cm2, total light dose not greater than 500 J/cm2.
Trial: 18225515
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (control group).
Trial: 15066462
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d orally)
Trial: 9571510
Drug: Low frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low frequency ultrasound treatment, started immediately after plaster removal
Trial: 2834976
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without acebutolol treatment
Trial: 28104641
Drug: Volumetric CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volumetric CT dose index
Trial: 26414587
Drug: Oral ginger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ginger for the first three days of the chemotherapy cycle (n = 30)
Trial: 19627223
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (health information brochures, a list of community resources, and a monthly telephone call to confirm contact information)
Trial: 16680254
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg IV at surgical skin closure
Trial: 16680254
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg IV immediately after anesthesia induction
Trial: 17179250
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg IV
Trial: 12088975
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg IV
Trial: 18450829
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg
Trial: 30265350
Drug: Manganese nanoparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manganese nanoparticles (NP‐Mn2O3) at 100 mg/kg
Trial: 30265350
Drug: Manganese nanoparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manganese nanoparticles (NP‐Mn2O3) at 50 mg/kg
Trial: 30265350
Drug: Manganese nanoparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manganese nanoparticles (NP‐Mn2O3) at 10 mg/kg
Trial: 30265350
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of Mn supplementation from 100 mg/kg to 50 or 10 mg/kg
Trial: 29628593
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg diluted in 20 mL normal saline (NS) over 10 min
Trial: 29628593
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) infusion of 20 mL over 10 min (Control Group)
Trial: 26661403
Drug: FEC (5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2, day 1, every 3 weeks)
Trial: 26661403
Drug: EP (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP (epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, day 1, every 3 weeks)
Trial: 10803490
Drug: Diltiazem-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem-based treatment strategy
Trial: 7546987
Drug: Long term
RxNorm normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term oral anticoagulant treatment
Trial: 31048181
Drug: Grape byproduct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape byproduct (0; 100; 200; and 300 g/kg DM)
Trial: 27854065
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text message reminders for the first 2 weeks, then once weekly thereafter for 3 months.
Trial: 22248554
Drug: Front-only suspension
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-only suspension (FS)
Trial: 22248554
Drug: Front-and-rear suspension
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-and-rear suspension (FRS)
Trial: 19679248
Drug: Amlodipine-based therapy
RxNorm normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-based therapy
Trial: 17288679
Drug: Atenolol-based therapy
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol-based therapy
Trial: 11246536
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients with total cholesterol > 5.2 mmol/L taking low-dose aspirin)
Trial: 9728805
Drug: Chemotherapy (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (specific regimen not detailed), evaluated at baseline, 7 days, 14 days, and 25 days post-treatment.
Trial: 9728805
Drug: Pre-treatment values
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment values of Hb < or = 9 g/dl in leukemia patients.
Trial: 10806134
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg)
Trial: 9799042
Drug: Lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20 mg)
Trial: 7995007
Drug: Enalapril during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril during angiotensin II infusion
Trial: 7995007
Drug: Lisinopril during
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril during angiotensin II infusion
Trial: 5356549
Drug: Concurrent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent infusion of amino-acids and hormones (secretin and pancreozymin)
Trial: 5356549
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of amino-acids or hormones individually
Trial: 29548608
Drug: Trivalent influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent influenza vaccine (TIV)
Trial: 30947385
Drug: Oral healthcare
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral healthcare motivation intervention group
Trial: 12671693
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (initial dose 150 IU kg(‐1) three times weekly)
Trial: 10872533
Drug: Potato carbohydrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato carbohydrates (g)
Trial: 10872533
Drug: Cereal carbohydrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal carbohydrates (g)
Trial: 10872533
Drug: Fruit carbohydrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit carbohydrates (g)
Trial: 10872533
Drug: Milk carbohydrates
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk carbohydrates (g)
Trial: 3987788
Drug: Procyclidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procyclidine (10 mg) - intravenous administration
Trial: 3987788
Drug: Procyclidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procyclidine (10 mg) - oral administration
Trial: 31571412
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg orally every 6 hours for 7 days
Trial: 28731373
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus 1% Metformin Gel (MF)
Trial: 11317472
Drug: MPPG (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPPG (3 x 150 mg daily)
Trial: 8496526
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release propranolol (mean 293 mg/day)
Trial: 8496526
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release diltiazem (mean 350 mg/day)
Trial: 8496526
Drug: Nifedipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (mean 79 mg/day)
Trial: 30380020
Drug: Extending Treatment
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extending Treatment Effectiveness of Naltrexone (EXTEND) trial
Trial: 21481280
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin/Vinorelbine (PLD/VNB) - PLD 40 mg/m2 on day 1, VNB 30 mg/m2 on days 1, 15, cycles every 4 weeks
Trial: 16414394
Drug: Endovenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous laser treatment with a wavelength of 810 nm
Trial: 26577034
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (2 g)
Trial: 25913660
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (wrist arthroscopy and percutaneous antegrade screw fixation)
Trial: 21542026
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg alcohol
Trial: 22841455
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of alcohol (0.4 g/kg and 0.6 g/kg)
Trial: 18652273
Drug: ART (atraumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART (atraumatic restorative treatment) approach using Ketac‐Molar (3M ESPE) ionomer cement
Trial: 8817136
Drug: Crystalloid cardioplegia
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid cardioplegia buffered with bicarbonate (St Thomas' II solution)
Trial: 19114438
Drug: High-volume Dysport
RxNorm normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume Dysport (500 U/5 mL)
Trial: 15025796
Drug: PVI 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PVI 5-FU 300 mg/m2 daily + mitomycin-C 7 mg/m2 every 6 weeks
Trial: 11561260
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine 60 microg/kg/min
Trial: 8181888
Drug: oral propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral propafenone (600 mg as a loading dose followed after 8 h by 300 mg t.i.d.)
Trial: 8181888
Drug: digoxin plus
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: digoxin plus quinidine (total dose, 1350 mg)
Trial: 2967304
Drug: Prednisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (50 mg/day)
Trial: 26484407
Drug: Ratio of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ratio of IGFBP-1 to fasting insulin
Trial: 26484407
Drug: Homeostasis model
RxNorm normalized name: CALCIUM HOMEOSTASIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeostasis model assessment-insulin resistance
Trial: 26484407
Drug: Corrected insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corrected insulin release at the glucose peak (CIRgp)
Trial: 16091912
Drug: 0.5% nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% nifedipine ointment (n=32) every 8 h for 8 weeks
Trial: 1350407
Drug: Acitretin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (30 mg daily for the first 4 weeks, then adjusted dose of 10-50 mg/day for 12 weeks)
Trial: 1350407
Drug: Etretinate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (30 mg daily for the first 4 weeks, then adjusted dose of 10-50 mg/day for 12 weeks)
Trial: 2938614
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g day‐1) with R warfarin (15 mg)
Trial: 2938614
Drug: Warfarin enantiomers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin enantiomers (15 mg) alone
Trial: 26482723
Drug: S-1 combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 combined with cisplatin plus concurrent chemoradiotherapy (SCCC)
Trial: 26482723
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus concurrent chemoradiotherapy (CCC)
Trial: 18460401
Drug: gel‐to‐foam dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel‐to‐foam dentifrice
Trial: 12956346
Drug: Microabrasion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microabrasion treatment
Trial: 12956346
Drug: Control slides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control slides (no treatment)
Trial: 10715523
Drug: SBAS4 hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBAS4 hepatitis B vaccine
Trial: 10715523
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine with alternative formulation on alum
Trial: 1622916
Drug: Oral ritodrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ritodrine (60 mg/day) in amniocentesis group
Trial: 1622916
Drug: No ritodrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ritodrine treatment in both groups
Trial: 24552755
Drug: Systane Ultra
RxNorm normalized name: Systane Ultra
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systane Ultra lubricant eye drops (applied twice a day for 2 weeks)